Business Wire

Historic Partnership between the Weizmann Institute of Science and Institut Curie

Share

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.

Collaborative research programs

This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot. Each research program will be organized around a pair of researchers with a scientist from Institut Curie and a scientist from the Weizmann Institute of Sciences, who will receive support on the annual basis. This partnership also includes exchanges of scientists and a Curie-Weizmann symposium organized every two years, with alternate locations in Rehovot, Israel, and in Paris, which will be focused on one of the subjects of research cooperation.
To finance the start of this cooperation, Institut Curie and the Weizmann Institute of Sciences will finance this research program for €200,000 each, and will organize a joint fundraiser with philanthropists and corporate sponsors.

Projects with high hopes
There are numerous common interests between the two Institutes. They can range from the description of defects in cell nuclei to the mechanics of cell migration, or the behavior of neural networks. A few examples of exciting ongoing projects are highlighted below.
During his sabbatical visit at Institut Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in several projects ranging from cell migration to collective cell behaviors and neuron growth. For instance, he developed a theory in collaboration with Raphael Voituriez (Sorbonne University), which explains the observations of the team of Matthieu Piel (Institut Curie) on the links between persistence and speed of migrating cells. This theory gave rise to collaborative developments between these three teams to predict important aspects of the migratory behavior of immune cells.
He also collaborated with Pascal Silberzan at Institut Curie to understand the behavior of cells packed at very high density on a surface. This joint work combining experiments and theory, has highlighted the importance of an intrinsic biological ageing of the cell population. This project has helped understanding how cells can come to an arrest while maintaining a capacity to respond to external perturbations such as an injury.
Elisha Moses (Weizmann Institute) has a longstanding interaction with the group of Professor Jean-Louis Viovy (Institut Curie), now headed by Stéphanie Descroix, on the applications of microfluidic devices to the study of living neuronal networks. He spent three months in Paris, during which he and Dr. Catherine Villard of the Descroix lab developed an optogenetic assay for guiding axonal growth. This work has the potential for controlling growth of neurons and of neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two talented researchers who were working on the project as students, have now graduated and branched off into very interesting conceptual and practical applications of this approach.

An important complementarity
The two institutions are both highly complementary and display many mutually common attributes.
Institut Curie is the premier research center in France conducting cancer research, including all facets of carcinogenesis. Its research center brings together 1,200 researchers working in 12 joint research units organized in four areas based on natural scientific interactions and robust medical potentiality. A strong advocate of international cooperation , it welcomes more than 80 nationalities. Equipped with advanced technology platforms, it is an important resource for researchers around the world. Institut Curie is also a state-of-the-art hospital complex that provides care and support for all cancer types and welcomes more than 50,000 patients each year. It has developed particularly innovative treatments directly from the work of its research center. Institut Curie also trains students in science and cancer research with the goal of increasing the knowledge about the topic.
The Weizmann Institute of Science is among the ten premier institutes of fundamental research in the world: 2,500 scientists work on its campus in Rehovot in the complementary fields of mathematics and computer science, physics, biology, chemistry, and biochemistry. The Weizmann Institute of Science has a long history of research and discoveries rooted in a mission of advancement of science for the benefit of humanity; cancer research accounts for 40% of the total budget of the Institute, which shapes and hosts a large part of the leadership in Israel and contributes to the advancement and understanding of scientific issues among all audiences.
Both institutions have powerful means of technology transfer that leverage the discoveries of their labs for the benefit of patients, whether through the creation of medications, medical devices or other technologies.

A shared vision of science
Science at the service of people - this is the best way to describe the credo of the two institutes, both of which were founded upon great personalities who have made an important mark in the history of the world.
Chaim Weizmann, chemist and author of many discoveries and publications, is the founder of the Weizmann Institute, and was the first president of the State of Israel between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the Radium Institute in 1909. The first female professor and holder of a chair position at the Sorbonne, the first woman to win two Nobel prizes and be enshrined at the Pantheon in Paris on her own merit. In many ways, these two scientists have had a remarkable journey.
But beyond these prestigious founders, the two institutes share the same vision of science, at the service of people and driven by strong values, the same curiosity for discovery and knowledge at the service of human health.
The Weizmann Institute of Science and Institut Curie also share a common belief that international collaborations in the field of institut-curie.org science and the exchange of ideas across interdisciplinary boundaries can accelerate progress to the benefit of humanity.
It is this common ground which today enables this collaboration to take root and which will tomorrow allow us to multiply efforts and as a result enjoy major new discoveries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yohan Philippe
yohan.philippe@curie.fr
+33 (0)1 56 24 55 53

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FES Super Extends Partnership with SS&C28.5.2025 01:13:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the Fire and Emergency Services Superannuation Fund (“FES Super”) has signed a long-term agreement to extend its existing partnership with SS&C. The renewal reinforces SS&C’s leadership and continued growth in the Australian superannuation market, following several recent strategic wins in the region. FES Super leverages SS&C Bluedoor, a cloud-hosted registry platform, to manage its administration needs. The platform enables real-time automation and straight-through processing, helping streamline operations and improving member experiences. SS&C also provides member digital and reporting services to the fund. “Our top priority is acting in the best interests of our members,” said Adrian Rutter, Fund Secretary at FES Super. “SS&C’s flexible, customizable tools and consistent service enable us to continue doing just that. By leveraging Bluedoor’s integration capabilities and cloud-native services, we can efficiently deliver

Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 22:48:00 EEST | Press release

Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo

Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 18:46:00 EEST | Press release

Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de

New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 18:44:00 EEST | Press release

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,

LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 18:00:00 EEST | Press release

LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances automated testing workflows by enabling the generation of new test cases using real execution data. Developers can leverage

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye